GO:0050728 negative regulation of inflammatory response: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050728 (negative regulation of inflammatory response) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of inflammation.
• This process is essential for resolving inflammation and preventing chronic inflammatory and autoimmune diseases.
• Key negative regulators include IL-10, SOCS proteins, A20 (TNFAIP3), USP38, RNF99, and miR-21, which act at multiple checkpoints.
• Dysregulation of negative regulation of inflammatory response contributes to sepsis, inflammatory bowel disease, cancer, and fibrosis.
• CRISPR knockout, knock-in, and overexpression models enable causal dissection of these regulatory circuits.
• Targeting negative regulators is a promising therapeutic strategy for inflammatory diseases.
Description
Inflammation is a protective response to infection and injury, but it must be tightly controlled to avoid tissue damage and chronic disease. The Gene Ontology term GO:0050728, negative regulation of inflammatory response, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of the inflammatory response. This term is fundamental for understanding how the immune system resolves inflammation and maintains homeostasis. Negative regulators of inflammation act at multiple levels, from extracellular cytokines such as IL-10 to intracellular ubiquitin editors and microRNAs. Their dysfunction is linked to a wide range of pathologies, including endotoxin tolerance, compensatory anti-inflammatory response syndrome, pulmonary fibrosis, and cancer. Researchers studying this process aim to identify the molecular brakes that keep inflammation in check and to harness them for therapeutic benefit. This article provides a comprehensive overview of the mechanisms, key genes, and research methods used to study negative regulation of inflammatory response, with a focus on CRISPR-based approaches for functional validation.
negative regulation of inflammatory response At A Glance
| GO ID | GO:0050728 |
|---|---|
| GO term | negative regulation of inflammatory response |
| Ontology | biological_process |
| Synonym | anti-inflammatory response; down regulation of inflammatory response; down-regulation of inflammatory response; downregulation of inflammatory response; inhibition of inflammatory response |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of the inflammatory response |
| Related processes | Resolution of inflammation, endotoxin tolerance, compensatory anti-inflammatory response syndrome |
| Key regulators | IL-10, SOCS1/3, A20 (TNFAIP3), USP38, RNF99, miR-21 |
| Disease relevance | Sepsis, inflammatory bowel disease, fibrosis, cancer, autoimmune diseases |
What Is GO:0050728?
According to the Gene Ontology, negative regulation of inflammatory response (GO:0050728) is any process that stops, prevents, or reduces the frequency, rate, or extent of the inflammatory response. In other words, it encompasses all molecular and cellular events that dampen or resolve inflammation, including the action of anti-inflammatory cytokines, intracellular negative feedback loops, and epigenetic regulators. This term is a biological process and is distinct from positive regulation of inflammatory response.
Why Is negative regulation of inflammatory response Important in Cell Biology?
Negative regulation of inflammatory response is critical for preventing excessive tissue damage and chronic inflammation. Without proper control, inflammation can become persistent and contribute to a wide range of diseases, including autoimmune disorders, fibrosis, and cancer. Understanding the molecular mechanisms that restrain inflammation is essential for developing new therapies that promote resolution rather than simply blocking pro-inflammatory pathways.
• Prevents tissue damage from uncontrolled inflammation.
• Maintains immune homeostasis and prevents autoimmunity.
• Enables resolution of acute inflammation and return to tissue homeostasis.
• Dysregulation leads to chronic inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis.
• Plays a key role in endotoxin tolerance and compensatory anti-inflammatory response syndrome in sepsis.
• Involved in pulmonary fibrosis through IL-33 receptor signaling.
• Negatively regulates TLR-mediated inflammatory responses via ubiquitination.
• Modulated by retinoic acid and NF-kappaB/miR-21 signaling.
• Chromatin-regulated biphasic circuits coordinate IL-1beta-mediated inflammation.
• Targeting negative regulators offers therapeutic potential for inflammatory diseases.
What Happens During negative regulation of inflammatory response?
Initiation of anti-inflammatory signals
In simple terms: The body starts sending 'calm down' signals to stop inflammation.
Negative regulation of inflammatory response begins with the detection of pro-inflammatory signals and the subsequent induction of anti-inflammatory mediators. Key initiators include anti-inflammatory cytokines such as IL-10, which is produced by macrophages and T cells and acts to suppress pro-inflammatory cytokine production. Additionally, pattern recognition receptor signaling can induce negative feedback loops, such as the upregulation of SOCS proteins, which inhibit cytokine signaling. Non-coding RNAs, including microRNAs, also participate in the initiation of anti-inflammatory programs.
Intracellular negative feedback and ubiquitination
In simple terms: Inside cells, specific proteins tag other proteins for destruction to shut down inflammation.
Intracellular negative regulators act by modifying key signaling molecules. For example, the E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2, leading to its degradation and dampening of NF-kappaB activation. Similarly, USP38 reciprocally regulates IL-33 receptor-mediated inflammatory response and pulmonary fibrosis by deubiquitinating TRAF6. These ubiquitin-dependent mechanisms provide a rapid and reversible brake on inflammation.
Transcriptional and epigenetic control
In simple terms: Cells change which genes are turned on or off to reduce inflammation.
Transcriptional and epigenetic mechanisms are central to negative regulation of inflammatory response. A chromatin-regulated biphasic circuit coordinates IL-1beta-mediated inflammation, involving changes in chromatin accessibility that first promote then resolve inflammation. Retinoic acid abrogates LPS-induced inflammatory response via negative regulation of NF-kappaB/miR-21 signaling, illustrating how small molecules can modulate transcriptional programs. These layers of control ensure that inflammation is transient and self-limiting.
Resolution and tissue repair
In simple terms: Inflammation is turned off and tissues start to heal.
The final stage of negative regulation of inflammatory response involves the resolution of inflammation and initiation of tissue repair. This includes the clearance of apoptotic neutrophils, the switch from pro-inflammatory to pro-resolving lipid mediators, and the restoration of tissue homeostasis. Defects in this stage can lead to chronic inflammation and fibrosis, as seen in pulmonary fibrosis where IL-33 receptor signaling is dysregulated.
Key Genes Involved in GO:0050728 negative regulation of inflammatory response
The following genes and proteins are key players in negative regulation of inflammatory response, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL10 | Anti-inflammatory cytokine that suppresses pro-inflammatory cytokine production | Central regulator of inflammation resolution; target for autoimmune diseases |
| SOCS1 | Cytokine signaling suppressor | Negative feedback inhibitor of JAK/STAT pathway |
| SOCS3 | Cytokine signaling suppressor | Inhibits IL-6 and other pro-inflammatory cytokines |
| TNFAIP3 (A20) | Ubiquitin-editing enzyme that inhibits NF-kappaB | Key negative regulator of TLR and TNF signaling |
| USP38 | Deubiquitinase that stabilizes TRAF6 | Regulates IL-33 receptor-mediated inflammation and fibrosis |
| RNF99 | E3 ligase that ubiquitinates TAB2 | Negatively regulates TLR-mediated inflammatory response |
| TAB2 | Adaptor protein in TLR signaling | Target of RNF99-mediated ubiquitination |
| TRAF6 | E3 ligase in IL-33 receptor signaling | Regulated by USP38; involved in pulmonary fibrosis |
| NFKB1 | Transcription factor subunit | Central mediator of pro-inflammatory gene expression; target of negative regulation |
| MIR21 | MicroRNA that promotes inflammation | Negatively regulated by retinoic acid to dampen LPS response |
| IL1B | Pro-inflammatory cytokine | Subject to biphasic chromatin regulation |
| IL33 | Alarmin cytokine | Receptor signaling reciprocally regulated by TRAF6 and USP38 |
| TNF | Pro-inflammatory cytokine | Target of negative regulation by A20 and others |
| MYD88 | Adaptor in TLR signaling | Upstream of negative feedback loops |
| IRAK1 | Kinase in TLR signaling | Regulated by SOCS proteins |
| NFKBIA (IκBα) | Inhibitor of NF-kappaB | Rapidly degraded and resynthesized to terminate NF-kappaB response |
How Is negative regulation of inflammatory response Regulated?
Negative regulation of inflammatory response is itself tightly regulated at multiple levels. At the transcriptional level, anti-inflammatory genes such as IL10 are induced by transcription factors like Sp1 and STAT3. Post-transcriptionally, microRNAs such as miR-21 modulate the stability of pro-inflammatory transcripts, and their expression is controlled by NF-kappaB. At the protein level, ubiquitination and deubiquitination by enzymes like RNF99 and USP38 provide reversible switches. Additionally, chromatin remodeling controls the accessibility of inflammatory gene loci, as seen in the biphasic circuit for IL-1beta. These layers ensure that negative regulation is timely and context-specific.
negative regulation of inflammatory response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL10 | Inflammatory bowel disease, autoimmunity | IL10 knockout mice; CRISPR KO in macrophages |
| TNFAIP3 | Autoimmunity, lymphoma | A20 knockout mice; point mutation models |
| USP38 | Pulmonary fibrosis | Usp38 knockout mice; overexpression in lung fibroblasts |
| RNF99 | Sepsis, inflammatory diseases | Rnf99 knockout macrophages; TLR stimulation assays |
| MIR21 | LPS-induced inflammation | miR-21 knockout mice; retinoic acid treatment models |
Sepsis and endotoxin tolerance
In sepsis, the initial hyperinflammatory phase is followed by a compensatory anti-inflammatory response syndrome (CARS) that can lead to immunoparalysis. Negative regulation of inflammatory response is critical in this context, and non-coding RNAs have been implicated in regulating endotoxin tolerance and CARS. Dysregulation can result in either excessive inflammation or immunosuppression, both of which are detrimental.
Pulmonary fibrosis
Pulmonary fibrosis is characterized by excessive scarring due to chronic inflammation. The IL-33 receptor-mediated inflammatory response is reciprocally regulated by TRAF6 and USP38, and disruption of this balance can promote fibrosis. Thus, negative regulators of inflammation are potential therapeutic targets for fibrotic diseases.
Inflammatory bowel disease and autoimmunity
Chronic inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis are associated with impaired negative regulation of inflammatory response. For example, polymorphisms in TNFAIP3 (A20) are linked to autoimmune conditions. Enhancing negative regulatory pathways, such as IL-10 signaling, is a therapeutic strategy.
Cancer
Inflammation is a hallmark of cancer, and negative regulators of inflammation can influence tumor progression. For instance, the chromatin-regulated biphasic circuit for IL-1beta-mediated inflammation may impact the tumor microenvironment. Understanding these mechanisms could lead to new cancer immunotherapies.
From negative regulation of inflammatory response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate inflammatory response? | CRISPR knockout in macrophage cell lines (e.g., RAW264.7, THP-1) |
| What is the effect of a specific point mutation in gene X on inflammation? | CRISPR point mutation knock-in in primary macrophages |
| How does overexpression of gene X affect inflammation? | Lentiviral overexpression in macrophages or mice |
| What is the interactome of gene X during inflammation? | Tagged knock-in (e.g., FLAG, HA) followed by immunoprecipitation |
| Which genes are essential for negative regulation of inflammation? | Genome-wide CRISPR library screening in LPS-stimulated macrophages |
| How does gene X regulate inflammation in vivo? | Conditional knockout mice (e.g., myeloid-specific) |
How to Study the negative regulation of inflammatory response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify anti-inflammatory gene signatures |
| Proteomics | Protein abundance and modifications | Discover ubiquitination targets of RNF99 |
| CRISPR knockout screening | Gene essentiality for inflammation | Find novel negative regulators |
| ChIP-seq | Transcription factor binding and histone marks | Map chromatin changes during resolution |
| Immunoprecipitation | Protein-protein interactions | Study TRAF6-USP38 interaction |
| Reporter assays | NF-kappaB or cytokine promoter activity | Screen for inhibitors of inflammation |
| Flow cytometry | Immune cell activation markers | Assess macrophage polarization |
Transcriptomic profiling (RNA-seq)
RNA sequencing allows global assessment of gene expression changes during negative regulation of inflammatory response. For example, comparing LPS-stimulated macrophages with or without a negative regulator knockout can reveal the pathways controlled by that gene.
Proteomic and ubiquitinome analysis
Mass spectrometry-based proteomics can identify protein-protein interactions and ubiquitination events. This is particularly useful for studying E3 ligases like RNF99 and deubiquitinases like USP38.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of inflammatory response. For instance, screening for genes whose loss increases LPS-induced NF-kappaB activation can uncover new brakes on inflammation.
Imaging and reporter assays
Live-cell imaging of NF-kappaB translocation or cytokine reporter mice can visualize the dynamics of negative regulation. Chromatin conformation capture (Hi-C) can reveal epigenetic changes.
How CRISPR Can Be Used to Study GO:0050728 negative regulation of inflammatory response
Knockout
CRISPR knockout is used to delete candidate negative regulators and assess whether their loss exacerbates inflammation. For example, knocking out RNF99 in macrophages leads to increased TLR-mediated inflammatory response. This approach provides causal evidence for a gene's role in negative regulation.
Point Mutation
CRISPR point mutation knock-in can model disease-associated variants or disrupt specific domains. For instance, mutating the catalytic cysteine of USP38 can reveal whether its deubiquitinase activity is required for suppressing IL-33-mediated inflammation.
Knock-in
Knock-in of tagged versions (e.g., FLAG, GFP) allows for endogenous protein localization and interaction studies. This is valuable for tracking the dynamics of negative regulators during inflammation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can test whether increasing a gene's dosage enhances negative regulation. Overexpressing IL-10 or A20 can suppress inflammation in various models.
How EDITGENE Supports negative regulation of inflammatory response Research
Researchers studying negative regulation of inflammatory response-related genes often need to determine whether a candidate gene is causally involved in dampening inflammation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of inflammatory response research.
Frequently Asked Questions About negative regulation of inflammatory response
What is negative regulation of inflammatory response?
Negative regulation of inflammatory response (GO:0050728) is any process that stops, prevents, or reduces the frequency, rate, or extent of inflammation.
What genes are involved in negative regulation of inflammatory response?
Key genes include IL10, SOCS1, SOCS3, TNFAIP3 (A20), USP38, RNF99, and MIR21, among others.
How does IL-10 suppress inflammation?
IL-10 is an anti-inflammatory cytokine that inhibits pro-inflammatory cytokine production by macrophages and other immune cells.
What is the role of ubiquitination in negative regulation of inflammation?
Ubiquitination enzymes like RNF99 and USP38 modify signaling proteins such as TAB2 and TRAF6 to dampen inflammatory signaling.
How can CRISPR be used to study negative regulation of inflammatory response?
CRISPR knockout, knock-in, and overexpression models allow researchers to test the causal role of specific genes in suppressing inflammation.
What diseases are associated with defective negative regulation of inflammation?
Defective negative regulation is linked to sepsis, inflammatory bowel disease, pulmonary fibrosis, autoimmunity, and cancer.
What is endotoxin tolerance?
Endotoxin tolerance is a state of reduced responsiveness to LPS after prior exposure, involving negative regulation of inflammatory response and non-coding RNAs.
How does retinoic acid reduce inflammation?
Retinoic acid abrogates LPS-induced inflammatory response via negative regulation of NF-kappaB/miR-21 signaling.
What is the biphasic circuit for IL-1beta-mediated inflammation?
It is a chromatin-regulated mechanism that first promotes then resolves inflammation, involving dynamic changes in chromatin accessibility.
What methods are used to study negative regulation of inflammatory response?
Common methods include RNA-seq, proteomics, CRISPR screening, ChIP-seq, and reporter assays.
Conclusion
Negative regulation of inflammatory response (GO:0050728) is a vital biological process that prevents excessive inflammation and maintains tissue homeostasis. The intricate interplay of cytokines, ubiquitin editors, transcription factors, and non-coding RNAs ensures that inflammation is resolved in a timely manner. Dysregulation of these mechanisms contributes to a broad spectrum of diseases, from sepsis to fibrosis and cancer. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of new negative regulators and therapeutic targets. EDITGENE is committed to providing researchers with the tools needed to dissect these pathways and translate findings into clinical benefit.
References
- 2. Vergadi E et al.. 2018. Regulation of Endotoxin Tolerance and Compensatory Anti-inflammatory Response Syndrome by Non-coding RNAs.. Front Immunol 9:2705 PMID: 30515175
- 3. Yi XM et al.. 2022. Reciprocal regulation of IL-33 receptor-mediated inflammatory response and pulmonary fibrosis by TRAF6 and USP38.. Proc Natl Acad Sci U S A 119(10):e2116279119 PMID: 35238669
- 4. Zhang J et al.. 2023. E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2.. Cell Death Differ 30(4):966-978 PMID: 36681779
- 5. Nurrahmah QI et al.. 2021. Retinoic acid abrogates LPS-induced inflammatory response via negative regulation of NF-kappa B/miR-21 signaling.. Immunopharmacol Immunotoxicol 43(3):299-308 PMID: 33757404
- 6. Fok ET et al.. 2024. A chromatin-regulated biphasic circuit coordinates IL-1β-mediated inflammation.. Nat Genet 56(1):85-99 PMID: 38092881
- 7. Rutz S et al.. 2016. Regulation of Interleukin-10 Expression.. Adv Exp Med Biol 941:89-116 PMID: 27734410
- 8. Butchar JP et al.. 2006. Negative regulators of toll-like receptor 4-mediated macrophage inflammatory response.. Curr Pharm Des 12(32):4143-53 PMID: 17100617
